JunGi Hwang

13PUBLICATIONS
42CO-AUTHORS
PharmacogenomicsGene and molecular therapyToxicology (incl. clinical toxicology)Epigenetics (incl. genome methylation and epigenomics)Pharmacology and pharmaceutical sciences not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 13, 2025
Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor.

Seo Yeong Park, Jun Gi Hwang, Sung Kweon Cho

|Mar 31, 2025
A First-In-Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM-S401, a Novel siRNA-DegradaBALL Drug Targeting CTGF in Healthy Adults.

Ha-Yeon Kim, Jaeso Cho, Min Kyu Park

|Jun 21, 2024
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.

Kyung-Sang Yu, Hyunwook Ryu, Dongseong Shin

|Apr 15, 2024
The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium-glucose cotransporter-2 inhibitor, in type 2 diabetes.

Sae Im Jeong, Mu Seong Ban, Jun-Gi Hwang

|Apr 08, 2024
Comparison of the pharmacokinetic characteristics and bioequivalence between two nanosuspension formulations of megestrol acetate in healthy Korean male subjects.

Se Rin Park, Jun Gi Hwang, Sae Im Jeong

|Jan 12, 2023
Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject.

Jun Gi Hwang, Sae Im Jeong, Yu Kyong Kim

Pageof 3

Frequent Collaborators

7 joint publications

MinKyu Park

5 joint publications

SeungHwan Lee

4 joint publications

Sae Im Jeong

3 joint publications

In-Jin Jang